- Home
- BIVI
BIVI
BioVie Inc.
as 06-27-2025 3:30pm EST
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | CARSON CITY |
| Market Cap: | 18.6M | IPO Year: | N/A |
| Target Price: | $30.00 | AVG Volume (30 days): | 194.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.62 - $7.50 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BioVie Inc. News
BIVI Breaking Stock News: Dive into BIVI Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)
GlobeNewswire
3 days ago
BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress
ACCESS Newswire
11 days ago
New to The Street's Show #672 Airs Tonight on Fox Business Network at 10:30 PM EST
ACCESS Newswire
21 days ago
New to The Street Announces Upcoming Bloomberg Air Dates Featuring FLOKI, BioVie Pharmaceuticals, Beeline, Arrive AI, and Commercialville
ACCESS Newswire
a month ago
BioVie and Liberty Star Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
GlobeNewswire
a month ago
BioVie Enrolls First Patient in ADDRESS-LC Clinical Trial Assessing Novel Anti-Inflammatory Candidate Bezisterim for the Treatment of Neurological Symptoms Associated with Long COVID
GlobeNewswire
a month ago
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease on May 28, 2025
GlobeNewswire
2 months ago
BioVie to Present Rationale and Design of Phase 2 SUNRISE-PD Clinical Trial at the 30th World Congress on Parkinson’s Disease and Related Disorders (IAPRD 2025)
Compare BIVI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BIVI BioVie Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.